| Cat. No. |
Product Name |
Information |
| PC-49234 |
Y1693
|
Y1693 is a potent, orally active small-molecule RANKL inhibitor, effectively prevents RANKL-induced osteoclastogenesis (89% inhibition at 1 uM) and bone resorption. |
| PC-73379 |
AS2690168 free base
|
AS2690168 is a novel orally available, selective RANKL signal transduction inhibitor, reduces TRAP staining of sRANKL-stimulated RAW264 cells with IC50 of 0.28 uM, suppresses RANKL-induced osteoclastogenesis. |
| PC-73378 |
AS2690168
|
AS2690168 is a novel orally available, selective RANKL signal transduction inhibitor, reduces TRAP staining of sRANKL-stimulated RAW264 cells with IC50 of 0.28 uM, suppresses RANKL-induced osteoclastogenesis. |
| PC-38199 |
Bcl3 inhibitor JS6
|
Bcl3 inhibitor JS6 is a novel potent, antimetastatic Bcl3 inhibitor, targeting the Bcl3-p50 interaction site. |
| PC-43543 |
BAY 11-7082
|
BAY 11-7082 is a NF-κB inhibitor that selectively and irreversibly inhibits the TNF-α-inducible phosphorylation of IκBα (IC50=10 uM), also inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 uM and 0.96 uM, respectively. |
| PC-62804 |
SEMBL
|
SEMBL is a potent NF-κB inhibitor that inhibits DNA binding of NF-κB component p65. |
| PC-62155 |
Withaferin A
|
Withaferin A is a steroid lactone that displays anti-inflammatory, antitumor and antiangiogenic activity, potently inhibits NF-κB activation by preventing the TNF-induced activation of IKKβ via a thioalkylation-sensitive redox mechanism. |
